Literature DB >> 12708098

[Assisted dying and the principle of double effect].

Martin Klein1.   

Abstract

Direct active euthanasia is prohibited in most countries while passive and indirect is not. However, many arguments against the legalization of voluntary active euthanasia are flawed, because a critical ethical difference between passive and active euthanasia is difficult to establish especially when the passivity of the actor causes death. The crucial point is not activity or passivity but respect for the autonomy of individual human beings. In particular there appears to be little ethical difference between active and indirect euthanasia. Indirect euthanasia has often been justified by the doctrine of double effect (Thomas Aquinas), which I argue contains a logical fallacy. This rule does not allow foreseen and unwanted adverse effects of an action to occur when they are avoidable. In terminal sedation, an example for indirect euthanasia, hypoxemia and dehydration can easily be prevented by respirator therapy and fluid administration. Therefore the rule of double effect is not applicable. Indirect and direct active euthanasia cannot be ethically distinguished by resorting to the doctrine of double effect.

Entities:  

Mesh:

Year:  2002        PMID: 12708098

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  3 in total

1.  [Limiting or withholding treatment: the principal of "primum nihil nocere"].

Authors:  Andreas Valentin
Journal:  Wien Klin Wochenschr       Date:  2006-06       Impact factor: 1.704

2.  Intentionally hastening death by withholding or withdrawing treatment.

Authors:  Georg Bosshard; Susanne Fischer; Agnes van der Heide; Guido Miccinesi; Karin Faisst
Journal:  Wien Klin Wochenschr       Date:  2006-06       Impact factor: 1.704

3.  [Emergency outpatient palliative care in acute situations by paramedics].

Authors:  Christoph H R Wiese; Utz Bartels; David Ruppert; Hartwig Marung; Bernhard M Graf; Gerd G Hanekop
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.